2.36

3.28% -0.08

After Hours: 2.36

Opus Genetics Inc (IRD)

Overview News Price History Discussions Forecast

Opus Genetics Inc stock is traded at $2.36, with a volume of 333.86K. It is down -3.28% in the last 24 hours and up +22.92% over the past month. Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Previous Close:

$2.44

Open:

$2.43

24h Volume:

333.86K

Relative Volume:

0.65

Market Cap:

$162.76M

Revenue:

$8.38M

Net Income/Loss:

$-27.19M

P/E Ratio:

-2.1651

EPS:

-1.09

Net Cash Flow:

$-13.59M

1W Performance:

+3.96%

1M Performance:

+22.92%

6M Performance:

+138.00%

1Y Performance:

+112.61%

1-Day Range:

$2.3201

$2.50

1-Week Range:

$2.21

$2.5907

52-Week Range:

$0.65

$2.5907

Opus Genetics Inc Stock (IRD) Company Profile

Name

Opus Genetics Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

248-681-9815

Address

8 DAVIS DRIVE, DURHAM

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

IRD's Discussions on Twitter

Compare IRD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IRD Opus Genetics Inc	2.36	168.27M	8.38M	-27.19M	-13.59M	-1.09
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Opus Genetics Inc Stock (IRD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-25	Initiated	B. Riley Securities	Buy
Nov-25-25	Initiated	Piper Sandler	Overweight
Oct-29-25	Initiated	Wedbush	Outperform
Oct-16-25	Initiated	Chardan Capital Markets	Buy
Apr-11-25	Initiated	Craig Hallum	Buy
Nov-13-24	Resumed	H.C. Wainwright	Buy

View All

Opus Genetics Inc Stock (IRD) Latest News

Dec 13, 2025

Opus Genetics (NASDAQ:IRD) Upgraded at Wall Street Zen - Defense World

Dec 13, 2025

Dec 12, 2025

Insider Selling: Opus Genetics (NASDAQ:IRD) Director Sells 4,000,000 Shares of Stock - MarketBeat

Dec 12, 2025

Dec 11, 2025

Foundation Fighting Blindness Retinal Degeneration Fund Sells 4,000,000 Shares of Opus Genetics Inc (IRD) - GuruFocus

Dec 11, 2025

Foundation fighting blindness sells $8.6 million in Opus Genetics (IRD) By Investing.com - Investing.com Australia

Dec 11, 2025

Foundation fighting blindness sells $8.6 million in Opus Genetics (IRD) - Investing.com

Dec 11, 2025

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference | Associated Press | syndication news - Enidnews.com

Dec 11, 2025

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference - GlobeNewswire

Dec 11, 2025

Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27% - simplywall.st

Dec 11, 2025

Dec 10, 2025

B. Riley Securities Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - Nasdaq

Dec 10, 2025

B. Riley Initiates Opus Genetics at Buy With $9 Price Target - marketscreener.com

Dec 10, 2025

Dec 09, 2025

Opus Genetics Says Independent Panel Backs Phase 1/2 Trial in Best Disease After Safety Review - marketscreener.com

Dec 09, 2025

Opus Genetics rises on update from eye disease study (IRD) - Seeking Alpha

Dec 09, 2025

Opus Genetics (IRD) Advances in Clinical Trial for Best Disease Treatment - GuruFocus

Dec 09, 2025

Opus Genetics advances Best disease gene therapy trial after positive safety review - Investing.com Canada

Dec 09, 2025

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease - marketscreener.com

Dec 09, 2025

Dec 05, 2025

Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Dec 05, 2025

Is Opus Genetics Inc. stock positioned well for digital economy2025 Earnings Impact & Daily Market Momentum Tracking - Newser

Dec 05, 2025

Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 05, 2025

Dec 04, 2025

How Opus Genetics Inc. (R3X1) stock trades after rate cutsMarket Risk Analysis & Smart Allocation Stock Reports - Newser

Dec 04, 2025

Why Opus Genetics Inc. (R3X1) stock gets analyst attentionOptions Play & High Accuracy Trade Signal Alerts - Newser

Dec 04, 2025

Equities Analysts Offer Predictions for Opus Genetics FY2025 Earnings - MarketBeat

Dec 04, 2025

How Opus Genetics Inc. (R3X1) stock trades under stagflationAnalyst Downgrade & Fast Entry High Yield Stock Tips - Newser

Dec 04, 2025

Why institutional investors increase stakes in Opus Genetics Inc. (R3X1) stockMarket Growth Summary & Verified Entry Point Signals - Newser

Dec 04, 2025

Will Opus Genetics Inc. (R3X1) stock outperform small cap peers2025 Market WrapUp & Growth Focused Stock Reports - Newser

Dec 04, 2025

Brokers Issue Forecasts for Opus Genetics FY2025 Earnings - Defense World

Dec 04, 2025

Dec 03, 2025

Opus Genetics (NASDAQ:IRD) Upgraded to "Strong-Buy" at Brookline Capital Management - MarketBeat

Dec 03, 2025

Why Opus Genetics Inc. stock remains on buy listsJuly 2025 Opening Moves & Real-Time Market Sentiment Alerts - Newser

Dec 03, 2025

Brookline Capital Management Upgrades Opus Genetics (NASDAQ:IRD) to Strong-Buy - Defense World

Dec 03, 2025

Dec 02, 2025